108 studies found for:    daclizumab
Show Display Options
Rank Status Study
1 Terminated
Has Results
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Conditions: Aplastic Anemia;   Pure Red Cell Aplasia;   Diamond Blackfan Anemia
Intervention: Drug: Daclizumab
2 Completed Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Condition: Renal Transplantation
Interventions: Drug: Thymoglobulin (ATG);   Drug: Daclizumab
3 Completed
Has Results
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
Condition: Kidney Transplantation
Interventions: Biological: DT;   Drug: Daclizumab;   Biological: KLH
4 Suspended Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Conditions: Hodgkin Disease;   Hodgkin Lymphoma
Interventions: Procedure: Auto stem cell transplant;   Drug: BEAM;   Radiation: 111In-daclizumab;   Radiation: 90Y-daclizumab
5 Completed
Has Results
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Conditions: Anterior Uveitis;   Arthritis, Juvenile Idiopathic;   Iritis;   Immunosuppression
Intervention: Drug: Daclizumab
6 Completed A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
Condition: Heart Transplantation
Interventions: Drug: Daclizumab;   Drug: Mycophenolate mofetil;   Drug: Silrolimus
7 Completed
Has Results
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Choroidal Neovascularization
Interventions: Drug: Intravenous Daclizumab;   Drug: Intravenous Infliximab;   Other: Observation;   Drug: Oral Rapamycin
8 Completed
Has Results
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BIIB019 (Daclizumab High Yield Process);   Drug: Interferon beta-1a Placebo;   Biological: Interferon beta-1a;   Drug: Daclizumab High Yield Process Placebo
9 Completed A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Condition: Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Intervention: Drug: Daclizumab
10 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
11 Completed An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Probe drug cocktail;   Biological: BIIB019 (Daclizumab)
12 Completed Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
Condition: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Intervention: Drug: CHOP-daclizumab
13 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
14 Completed Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
15 Completed Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Condition: Graft vs Host Disease
Intervention: Drug: daclizumab, infliximab
16 Completed Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
17 Completed Daclizumab and Sirolimus to Treat Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
18 Completed Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
Condition: Non-Infectious Intermediate and Posterior Uveitis
Intervention: Drug: Daclizumab
19 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Condition: Heart Transplantation
Interventions: Drug: Daclizumab;   Drug: Methylprednisolone;   Drug: Mycophenolate mofetil;   Drug: Placebo;   Drug: cyclosporine
20 Active, not recruiting Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BIIB019 (Daclizumab);   Biological: trivalent seasonal influenza vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years